There have been many developments for the management of renal cell carcinoma (RCC) in recent years. Tivozanib, a kinase inhibitor, has been approved by the USFDA for treatment of advanced RCC in adult patients. Tivozanib is a tyrosine kinase inhibitor that inhibits the phosphorylation of vascular endothelial growth factor receptors (VEGFR). These mechanisms inhibit tumor growth and progression, successfully treating advanced carcinomas, including RCC.
1 In March 2021, Tivozanib has been approved by FDA for treating adult patients with relapsed or refractory advanced RCC, following two or more prior systemic therapies. 2 TIVO-3 Trial The TIVO-3 is a randomized (1:1), open-label, multicenter trial evaluating the efficacy of tivozanib compared with sorafenib in adults with advanced RCC who had received at least two or three prior systemic treatments. The previous systemic therapies…
